Efficacy and Safety of Radiotherapy Combined With Apatinib Mesylate in the Treatment of Rhabdomyosarcoma in Children

Phase 1/2 Unknown 48 enrolled Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

SequentialOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of radiotherapy combined with apatinib mesylate in the treatment of rhabdomyosarcoma in children.

Timeline

Start: 2019-01-01
Primary completion: 2020-04-01
Completion: 2020-04-01

Publications

Vatner R, James CD, Sathiaseelan V, Bondra KM, Kalapurakal JA, Houghton PJ. Radiation therapy and molecular-targeted agents in preclinical testing for immunotherapy, brain tumors, and sarcomas: Opportunities and challenges. Pediatr Blood Cancer. 2021 May;68 Suppl 2:e28439. doi: 10.1002/pbc.28439. Epub 2020 Aug 22.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rivoceranib	Small molecule	250 mg	Oral

Efficacy and Safety of Radiotherapy Combined With Apatinib Mesylate in the Treatment of Rhabdomyosarcoma in Children

Summary

Timeline

Publications

Drugs

Indications